Syndax Pharmaceuticals, Inc. (SNDX)
USD 11.24
(0.72%)
USD 11.24
(0.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 229.95 Million USD | 51.53% |
| 2022 | 151.75 Million USD | 33.72% |
| 2021 | 113.48 Million USD | 55.59% |
| 2020 | 72.94 Million USD | 23.51% |
| 2019 | 59.05 Million USD | -23.69% |
| 2018 | 77.39 Million USD | 20.81% |
| 2017 | 64.06 Million USD | 42.4% |
| 2016 | 44.98 Million USD | 112.8% |
| 2015 | 21.14 Million USD | -0.9% |
| 2014 | 21.33 Million USD | 148.89% |
| 2013 | 8.57 Million USD | -1.87% |
| 2012 | 8.73 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 102.07 Million USD | 31.35% |
| 2024 Q1 | 79.51 Million USD | 2.06% |
| 2024 Q2 | 77.71 Million USD | -2.26% |
| 2023 Q2 | 49.67 Million USD | 7.96% |
| 2023 Q4 | 77.9 Million USD | 38.24% |
| 2023 Q1 | 46.01 Million USD | 9.47% |
| 2023 FY | 229.94 Million USD | 51.52% |
| 2023 Q3 | 56.35 Million USD | 13.44% |
| 2022 Q2 | 37.72 Million USD | 2.35% |
| 2022 Q4 | 42.03 Million USD | 19.61% |
| 2022 FY | 151.75 Million USD | 33.72% |
| 2022 Q1 | 36.85 Million USD | 19.56% |
| 2022 Q3 | 35.14 Million USD | -6.85% |
| 2021 Q3 | 32.4 Million USD | 42.68% |
| 2021 Q4 | 30.82 Million USD | -4.88% |
| 2021 Q2 | 22.71 Million USD | -17.53% |
| 2021 Q1 | 27.54 Million USD | 36.08% |
| 2021 FY | 113.48 Million USD | 55.59% |
| 2020 Q3 | 20.23 Million USD | 19.09% |
| 2020 Q2 | 16.98 Million USD | 9.76% |
| 2020 FY | 72.94 Million USD | 23.51% |
| 2020 Q1 | 15.47 Million USD | 6.13% |
| 2020 Q4 | 20.24 Million USD | 0.04% |
| 2019 Q1 | 15.19 Million USD | -22.94% |
| 2019 FY | 59.05 Million USD | -23.69% |
| 2019 Q4 | 14.58 Million USD | 7.81% |
| 2019 Q3 | 13.52 Million USD | -14.12% |
| 2019 Q2 | 15.75 Million USD | 3.71% |
| 2018 Q4 | 19.71 Million USD | 8.19% |
| 2018 FY | 77.39 Million USD | 20.81% |
| 2018 Q1 | 20.13 Million USD | -2.67% |
| 2018 Q3 | 18.22 Million USD | -5.74% |
| 2018 Q2 | 19.33 Million USD | -3.97% |
| 2017 FY | 64.06 Million USD | 42.4% |
| 2017 Q1 | 13.48 Million USD | 17.79% |
| 2017 Q2 | 14.14 Million USD | 4.93% |
| 2017 Q3 | 15.75 Million USD | 11.34% |
| 2017 Q4 | 20.68 Million USD | 31.31% |
| 2016 Q1 | 9.05 Million USD | 81.74% |
| 2016 FY | 44.98 Million USD | 112.8% |
| 2016 Q3 | 15.54 Million USD | 73.88% |
| 2016 Q2 | 8.93 Million USD | -1.31% |
| 2016 Q4 | 11.44 Million USD | -26.36% |
| 2015 Q1 | 4.43 Million USD | 34.81% |
| 2015 Q3 | 6.16 Million USD | 10.87% |
| 2015 FY | 21.14 Million USD | -0.9% |
| 2015 Q2 | 5.55 Million USD | 25.37% |
| 2015 Q4 | 4.98 Million USD | -19.13% |
| 2014 Q4 | 3.28 Million USD | -57.48% |
| 2014 Q3 | 7.73 Million USD | 22.33% |
| 2014 FY | 21.33 Million USD | 148.89% |
| 2014 Q2 | 6.32 Million USD | 58.77% |
| 2014 Q1 | 3.98 Million USD | 38.35% |
| 2013 Q1 | 1.31 Million USD | 99976.34% |
| 2013 Q2 | 2.09 Million USD | 59.95% |
| 2013 Q3 | 2.28 Million USD | 8.92% |
| 2013 Q4 | 2.87 Million USD | 26.05% |
| 2013 FY | 8.57 Million USD | -1.87% |
| 2012 FY | 8.73 Million USD | 0.0% |
| 2012 Q4 | 1310.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agenus Inc. | 78.18 Million USD | -194.123% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1324.648% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -35.845% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -52.757% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 39.565% |
| MiMedx Group, Inc. | 229.72 Million USD | -0.099% |
| Novavax, Inc. | 779.12 Million USD | 70.486% |
| Seer, Inc. | 110.49 Million USD | -108.122% |
| Acelyrin, Inc. | 422.06 Million USD | 45.517% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -36.523% |
| IO Biotech, Inc. | 91.44 Million USD | -151.473% |
| Ardelyx, Inc. | 169.93 Million USD | -35.317% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -43.913% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1553.199% |
| Fortress Biotech, Inc. | 200.19 Million USD | -14.865% |
| Fortress Biotech, Inc. | 200.19 Million USD | -14.865% |
| Geron Corporation | 70.44 Million USD | -226.449% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 48.41% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -602.235% |
| Incyte Corporation | 1.19 Billion USD | 80.684% |
| Innoviva, Inc. | 132.15 Million USD | -74.005% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2621.027% |
| ChromaDex Corporation | 56.37 Million USD | -307.872% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -172.706% |
| MEI Pharma, Inc. | 34.78 Million USD | -561.072% |
| NextCure, Inc. | 67.63 Million USD | -239.983% |
| Onconetix, Inc. | 34.9 Million USD | -558.754% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1704.127% |
| GlycoMimetics, Inc. | 39.28 Million USD | -485.344% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -45.712% |
| Vaxcyte, Inc. | 468.04 Million USD | 50.869% |
| Precigen, Inc. | 84.18 Million USD | -173.166% |
| Pharming Group N.V. | 225.49 Million USD | -1.979% |
| ContextLogic Inc. | 387 Million USD | 40.58% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1114.824% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -179.763% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -76.531% |
| AlloVir, Inc. | 180.93 Million USD | -27.093% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -846.055% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -43.238% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1783318.644% |
| Summit Therapeutics Inc. | 87.68 Million USD | -162.247% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -520.424% |
| Senti Biosciences, Inc. | 94.7 Million USD | -142.811% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -33.77% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -680.325% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -73.977% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -8257.147% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -332.843% |
| Chimerix, Inc. | 93.38 Million USD | -146.232% |
| PDS Biotechnology Corporation | 43.04 Million USD | -434.215% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1217.26% |
| CRISPR Therapeutics AG | 463.49 Million USD | 50.387% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -26.835% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -37.018% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -216.889% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -137.777% |
| Precision BioSciences, Inc. | 92.46 Million USD | -148.698% |
| Dyadic International, Inc. | 9.15 Million USD | -2412.418% |
| Elevation Oncology, Inc. | 45.44 Million USD | -406.005% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -933.362% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -14.34% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.225% |
| Aptorum Group Limited | 10.56 Thousand USD | -2176258.13% |
| Bicycle Therapeutics plc | 216.92 Million USD | -6.008% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -5733.364% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -602.901% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3315.863% |
| GT Biopharma, Inc. | 13.57 Million USD | -1593.827% |
| Alkermes plc | 996.24 Million USD | 76.918% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -225.742% |
| Jaguar Health, Inc. | 42.01 Million USD | -447.314% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -574.649% |
| AbCellera Biologics Inc. | 275.23 Million USD | 16.451% |
| PureTech Health plc | 144.59 Million USD | -59.031% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1084.2% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -0.557% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -507.235% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -171.441% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -846.055% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -145.998% |
| AnaptysBio, Inc. | 181.56 Million USD | -26.649% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -579.453% |
| ESSA Pharma Inc. | 32.13 Million USD | -615.607% |
| Molecular Templates, Inc. | 63.09 Million USD | -264.48% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1862.923% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 43.019% |
| Vaxxinity, Inc. | 56.05 Million USD | -310.259% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -353.621% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -645.176% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -183.677% |
| Structure Therapeutics Inc. | 102.77 Million USD | -123.745% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -305.141% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -86.118% |
| ImmuCell Corporation | 9.61 Million USD | -2291.03% |
| Lantern Pharma Inc. | 17.87 Million USD | -1186.271% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -674.725% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -676.714% |
| Opthea Limited | 191.96 Million USD | -19.788% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 6.202% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -647.308% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 9.483% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -4.605% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 11.36% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -325.211% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2213.969% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 11.44% |
| Aptose Biosciences Inc. | 52.35 Million USD | -339.212% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1495.753% |
| Soligenix, Inc. | 7.79 Million USD | -2849.924% |
| Century Therapeutics, Inc. | 56.07 Million USD | -310.112% |
| Kura Oncology, Inc. | 165.8 Million USD | -38.69% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -100.821% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2664.202% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -9166.215% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -113.517% |
| Autolus Therapeutics plc | 196.72 Million USD | -16.89% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -171.63% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -97.465% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1086.369% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 28.532% |
| GRI Bio, Inc. | 11.33 Million USD | -1929.603% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3159.123% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -75.279% |
| IGM Biosciences, Inc. | 265.59 Million USD | 13.418% |
| INmune Bio, Inc. | 29.89 Million USD | -669.18% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -33.265% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -470.403% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1339.069% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1360.809% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -270.308% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -113.867% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 16.591% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 23.718% |
| Verastem, Inc. | 92.08 Million USD | -149.722% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1181.866% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -23.814% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -89.408% |
| Histogen Inc. | 14.27 Million USD | -1511.225% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1332.901% |
| Surrozen, Inc. | 18.55 Million USD | -1139.644% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1441.763% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4417.551% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -285.356% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -796.612% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -389.201% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2912.691% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -29.089% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -374.641% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 6.143% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1396.456% |
| Apollomics, Inc. | 54.14 Million USD | -324.74% |
| Amarin Corporation plc | 272.35 Million USD | 15.569% |
| Mesoblast Limited | 5.9 Million USD | -3796.205% |
| Turnstone Biologics Corp. | 78.33 Million USD | -193.541% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 5.804% |
| Synaptogenix, Inc. | 8.31 Million USD | -2665.913% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1476.539% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 9.129% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -589.929% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2503.871% |
| Exelixis, Inc. | 1.58 Billion USD | 85.508% |
| Better Therapeutics, Inc. | 38.26 Million USD | -500.998% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 0.903% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 73.111% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1847.597% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2759.447% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -666.692% |
| Gritstone bio, Inc. | 148.37 Million USD | -54.983% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -233.939% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1305.568% |
| Avid Bioservices, Inc. | 25.99 Million USD | -784.575% |
| Insmed Incorporated | 949.26 Million USD | 75.775% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1365.628% |
| MediWound Ltd. | 18.86 Million USD | -1118.751% |
| OmniAb, Inc. | 83.89 Million USD | -174.097% |
| Alector, Inc. | 248.8 Million USD | 7.576% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 1.858% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -340.095% |
| Zai Lab Limited | 547.47 Million USD | 57.997% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 42.317% |
| Aura Biosciences, Inc. | 84.99 Million USD | -170.563% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 6.953% |
| Immunic, Inc. | 99.22 Million USD | -131.755% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -44.614% |
| Veracyte, Inc. | 357.93 Million USD | 35.755% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.449% |
| FibroGen, Inc. | 398.11 Million USD | 42.239% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1518.255% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3238.498% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3127.093% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 92.937% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -788.78% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 27.355% |
| TG Therapeutics, Inc. | 198.47 Million USD | -15.86% |
| Galecto, Inc. | 35.62 Million USD | -545.449% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -465.15% |
| Fortrea Holdings Inc. | 457.3 Million USD | 49.715% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -323.66% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -696.295% |
| XBiotech Inc. | 37.51 Million USD | -513.047% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -233.939% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1013.633% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -61.87% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -132.101% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -107.697% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 76.003% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -697.206% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 46.602% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -930.8% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -107.414% |
| NexImmune, Inc. | 28.16 Million USD | -716.38% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4057.587% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1185.197% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.832% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -803.233% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -80.978% |
| Ainos, Inc. | 12.95 Million USD | -1675.341% |
| Pluri Inc. | 22.48 Million USD | -922.927% |
| Prothena Corporation plc | 282.4 Million USD | 18.573% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -14.964% |
| Celularity Inc. | 215.05 Million USD | -6.927% |
| Rallybio Corporation | 78.93 Million USD | -191.332% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1076.717% |
| MeiraGTx Holdings plc | 151.07 Million USD | -52.209% |
| Omeros Corporation | 94.75 Million USD | -142.693% |
| Humacyte, Inc. | 23.49 Million USD | -878.653% |
| Immunocore Holdings plc | 308.04 Million USD | 25.349% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -6683.304% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -164.726% |
| Blueprint Medicines Corporation | 722.86 Million USD | 68.188% |
| CalciMedica, Inc. | 21.81 Million USD | -954.013% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -208.002% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -34.244% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 22.034% |
| Pulmatrix, Inc. | 22.03 Million USD | -943.443% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -565.087% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -158.765% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 58.309% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -216.955% |
| Cytokinetics, Incorporated | 173.61 Million USD | -32.453% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -568.102% |
| Nutriband Inc. | 5.73 Million USD | -3910.338% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -427.26% |
| Vor Biopharma Inc. | 126.03 Million USD | -82.451% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 80.663% |
| Evogene Ltd. | 27.79 Million USD | -727.47% |
| ProKidney Corp. | 151.52 Million USD | -51.763% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -210.016% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2889.428% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 62.562% |
| CorMedix Inc. | 48.95 Million USD | -369.699% |
| BioLineRx Ltd. | 50.8 Million USD | -352.648% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -52.591% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -503.998% |
| Atai Life Sciences N.V. | 125.78 Million USD | -82.815% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -181.671% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -182.468% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 8.948% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -602.364% |
| MediciNova, Inc. | 10.9 Million USD | -2009.618% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -78.508% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3067.618% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3718.456% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 51.727% |
| Biomea Fusion, Inc. | 126.13 Million USD | -82.308% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 82.471% |
| Mereo BioPharma Group plc | 35.84 Million USD | -541.577% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -20.339% |
| Absci Corporation | 73.66 Million USD | -212.158% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -733.71% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -72.134% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 5.041% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 12.247% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -10.558% |
| Allakos Inc. | 196.05 Million USD | -17.29% |
| Imunon, Inc. | 20.31 Million USD | -1032.197% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -102.658% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 37.616% |
| BioAtla, Inc. | 129.68 Million USD | -77.315% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1847.597% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1351.455% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -170.795% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -450.683% |
| XOMA Corporation | 46.46 Million USD | -394.919% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -106.847% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -61.413% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1671.739% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -121.843% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -33.021% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 9.738% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -514.719% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2695.857% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1268.285% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10012.447% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 23.174% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3317.495% |
| UroGen Pharma Ltd. | 138.88 Million USD | -65.568% |
| Sutro Biopharma, Inc. | 243 Million USD | 5.372% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -3061.044% |
| Orgenesis Inc. | 45.75 Million USD | -402.555% |
| Entera Bio Ltd. | 8.86 Million USD | -2495.418% |
| GH Research PLC | 41.22 Million USD | -457.843% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -794.484% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -176.876% |
| Xencor, Inc. | 306.97 Million USD | 25.091% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4560.972% |
| Replimune Group, Inc. | 234.77 Million USD | 2.053% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1022.28% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -19.895% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3317.495% |
| Portage Biotech Inc. | 18.19 Million USD | -1163.553% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3067.618% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -119.085% |
| OncoCyte Corporation | 25.63 Million USD | -796.961% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3672.454% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1907.094% |
| Purple Biotech Ltd. | -22.46 Million USD | 1123.519% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1295.352% |
| scPharmaceuticals Inc. | 65.17 Million USD | -252.809% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2620.468% |
| HilleVax, Inc. | 133.34 Million USD | -72.45% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2135.819% |
| Tharimmune, Inc. | 9.45 Million USD | -2332.032% |
| Genprex, Inc. | 31.06 Million USD | -640.341% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -22.625% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -632.874% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -29959.346% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4121.726% |
| OKYO Pharma Limited | 8243.57 USD | -2789395.328% |
| Savara Inc. | 15.74 Million USD | -1360.489% |
| Curis, Inc. | 58.35 Million USD | -294.06% |
| Daré Bioscience, Inc. | 33.6 Million USD | -584.195% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4415.553% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2982.08% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -750.988% |
| BeiGene, Ltd. | 3.28 Billion USD | 93.003% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1053.27% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 53.895% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -49.659% |
| Erasca, Inc. | 141.52 Million USD | -62.483% |
| bluebird bio, Inc. | 240.23 Million USD | 4.278% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4979.64% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 86.832% |
| DBV Technologies S.A. | 92.16 Million USD | -149.516% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4979.64% |
| Moderna, Inc. | 6.39 Billion USD | 96.404% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -439.684% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1500.682% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -244.753% |
| Travere Therapeutics, Inc. | 472 Million USD | 51.281% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -60.458% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -270.404% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -429.677% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -10.486% |
| MacroGenics, Inc. | 217.21 Million USD | -5.865% |
| RenovoRx, Inc. | 11.39 Million USD | -1917.848% |
| Adicet Bio, Inc. | 152.03 Million USD | -51.248% |
| Prime Medicine, Inc. | 186.63 Million USD | -23.208% |
| Aditxt, Inc. | 25.95 Million USD | -786.116% |
| Adagene Inc. | 41.83 Million USD | -449.717% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3045.703% |
| Quantum-Si incorporated | 111.65 Million USD | -105.943% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -33.811% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1477.429% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -541.935% |
| SciSparc Ltd. | 9.01 Million USD | -2451.925% |
| Vericel Corporation | 142.04 Million USD | -61.894% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2556.381% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -895.964% |
| Generation Bio Co. | 144.46 Million USD | -59.174% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -176.953% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -165.966% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 22.239% |
| Invivyd, Inc. | 205.75 Million USD | -11.761% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -218.677% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2351.926% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -205.57% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2135.384% |
| 2seventy bio, Inc. | 289.88 Million USD | 20.675% |
| ADMA Biologics, Inc. | 66.58 Million USD | -245.349% |
| Clene Inc. | 41.07 Million USD | -459.867% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1695.409% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -319.655% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3718.456% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 34.681% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -526.031% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -581.79% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -121.745% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -605.618% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -35.046% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 70.047% |
| Evaxion Biotech A/S | 22.27 Million USD | -932.573% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -69.653% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 2.098% |
| Trevena, Inc. | 38.41 Million USD | -498.636% |
| Surrozen, Inc. | 18.55 Million USD | -1139.644% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -187.64% |
| Cingulate Inc. | 22.75 Million USD | -910.379% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3169.327% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -414.819% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2692.757% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -124.218% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 69.506% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -270.451% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2530.646% |
| Kronos Bio, Inc. | 128.11 Million USD | -79.486% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -173.52% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7740.272% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -128.068% |
| Statera Biopharma, Inc. | 28.82 Million USD | -697.634% |
| ImmunityBio, Inc. | 362.87 Million USD | 36.629% |
| Korro Bio, Inc. | 84.53 Million USD | -172.025% |
| Kineta, Inc. | 21.15 Million USD | -986.945% |
| BioVie Inc. | 31.95 Million USD | -619.726% |
| Codexis, Inc. | 66.51 Million USD | -245.702% |
| Celularity Inc. | 215.05 Million USD | -6.927% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -1.471% |
| Celcuity Inc. | 66.23 Million USD | -247.203% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3412.323% |
| Cibus, Inc. | 320.3 Million USD | 28.208% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -434.777% |
| IN8bio, Inc. | 30.33 Million USD | -657.998% |
| Kodiak Sciences Inc. | 277.32 Million USD | 17.08% |
| Annexon, Inc. | 143.72 Million USD | -59.998% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -80.227% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -903.771% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -35830.313% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 70.503% |
| Eyenovia, Inc. | 25.4 Million USD | -805.101% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -63.884% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4034.376% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -190.592% |
| Arcellx, Inc. | 200.19 Million USD | -14.863% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -400.989% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -6.258% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2209.471% |
| Moolec Science SA | 52.75 Million USD | -335.927% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -276.123% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -394.1% |
| Royalty Pharma plc | 862.4 Million USD | 73.336% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -144.445% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2365.237% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -916.213% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -10.655% |
| Humacyte, Inc. | 23.49 Million USD | -878.653% |
| 89bio, Inc. | 151.2 Million USD | -52.082% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -186.969% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1481.527% |
| Genelux Corporation | 24.33 Million USD | -844.952% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -577.87% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -33.022% |
| Notable Labs, Ltd. | 14.77 Million USD | -1456.899% |
| Liquidia Corporation | 87.98 Million USD | -161.359% |
| Mustang Bio, Inc. | 48.5 Million USD | -374.122% |
| Immunovant, Inc. | 282.7 Million USD | 18.661% |
| Quantum-Si incorporated | 111.65 Million USD | -105.943% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -920.023% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -981.271% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -125.419% |
| Acasti Pharma Inc. | 11.3 Million USD | -1934.811% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -903.241% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1339.069% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -394.078% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -20167.764% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1347.526% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -688.675% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -455.659% |
| PepGen Inc. | 84.76 Million USD | -171.281% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -676.059% |
| United Therapeutics Corporation | 885.1 Million USD | 74.019% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -904.298% |
| Solid Biosciences Inc. | 104.31 Million USD | -120.442% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -602.675% |
| Immuneering Corporation | 58.41 Million USD | -293.67% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4417.551% |
| Silo Pharma, Inc. | 3.92 Million USD | -5763.397% |
| Belite Bio, Inc | 31.66 Million USD | -626.14% |
| XOMA Corporation | 46.46 Million USD | -394.919% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -240.42% |
| Bionomics Limited | 17.89 Billion USD | 98.715% |
| Apogee Therapeutics, Inc. | 93 Million USD | -147.254% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 744.49% |
| uniQure N.V. | 285.08 Million USD | 19.339% |
| Cassava Sciences, Inc. | 105.95 Million USD | -117.026% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3045.703% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -18.407% |
| Forte Biosciences, Inc. | 32.47 Million USD | -608.052% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2667.611% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -682.29% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4034.376% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1518.255% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2486.95% |
| Altimmune, Inc. | 30.55 Million USD | -652.566% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 46.229% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 744.49% |
| Compugen Ltd. | 43.97 Million USD | -422.967% |
| Peak Bio, Inc. | 1249.13 USD | -18409032.756% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -210.246% |
| Benitec Biopharma Inc. | 22.38 Million USD | -927.406% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 5.442% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -705.641% |
| Zura Bio Limited | 62.63 Million USD | -267.116% |
| PolyPid Ltd. | 21.04 Million USD | -992.678% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1312.841% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -705.641% |
| Instil Bio, Inc. | 85.78 Million USD | -168.059% |
| argenx SE | 1.53 Billion USD | 85.005% |
| Immunome, Inc. | 122.82 Million USD | -87.228% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -374.396% |
| Verona Pharma plc | 67.15 Million USD | -242.442% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -788.368% |
| Shattuck Labs, Inc. | 93.61 Million USD | -145.641% |
| CervoMed Inc. | 14.95 Million USD | -1437.355% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -225.239% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2591.409% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -350.89% |
| Moolec Science SA | 52.75 Million USD | -335.927% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1298.029% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -73.478% |
| Design Therapeutics, Inc. | 78.19 Million USD | -194.096% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -164.19% |
| NeurAxis, Inc. | 8.82 Million USD | -2506.834% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1727.207% |
| Lumos Pharma, Inc. | 38.66 Million USD | -494.734% |
| Achilles Therapeutics plc | 75.25 Million USD | -205.566% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -788.368% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1606.207% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -767.671% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7740.272% |
| Nutriband Inc. | 5.73 Million USD | -3910.338% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -107.577% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -313.192% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -351.962% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -247.893% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -324.872% |
| Palisade Bio, Inc. | 13.32 Million USD | -1626.381% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -406.406% |
| Beam Therapeutics Inc. | 554.19 Million USD | 58.507% |
| Neurogene Inc. | 55.58 Million USD | -313.713% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 7.459% |
| AEON Biopharma, Inc. | 48.42 Million USD | -374.827% |
| Sesen Bio, Inc. | 78.38 Million USD | -193.38% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -175.298% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1726.932% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 49.012% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -161.638% |
| Athira Pharma, Inc. | 125.46 Million USD | -83.28% |
| Vaccinex, Inc. | 23.45 Million USD | -880.405% |
| HCW Biologics Inc. | 21.02 Million USD | -993.586% |
| XOMA Corporation | 46.46 Million USD | -394.919% |
| Nektar Therapeutics | 190.9 Million USD | -20.456% |
| Arvinas, Inc. | 480 Million USD | 52.093% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10012.447% |
| Merus N.V. | 200.49 Million USD | -14.694% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -122.489% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -564.223% |
| Rezolute, Inc. | 70.38 Million USD | -226.7% |
| Clene Inc. | 41.07 Million USD | -459.867% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1304.001% |
| BeyondSpring Inc. | 24.86 Million USD | -824.81% |
| Synlogic, Inc. | 58.53 Million USD | -292.869% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1185.234% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -5019.19% |
| Peak Bio, Inc. | 1249.13 USD | -18409032.756% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -280.429% |
| Krystal Biotech, Inc. | 160.42 Million USD | -43.34% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 15.03% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 33.928% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -10562.14% |
| MannKind Corporation | 125.59 Million USD | -83.089% |
| Ikena Oncology, Inc. | 84.57 Million USD | -171.887% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2283.684% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -156.642% |
| Gossamer Bio, Inc. | 183.75 Million USD | -25.139% |
| CohBar, Inc. | 12.38 Million USD | -1756.22% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -353.344% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -733.71% |
| Legend Biotech Corporation | 583.14 Million USD | 60.567% |
| Mural Oncology plc | 192.07 Million USD | -19.723% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -242.464% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1324.281% |
| Disc Medicine, Inc. | 91.12 Million USD | -152.35% |
| Champions Oncology, Inc. | 28.11 Million USD | -718.051% |
| REGENXBIO Inc. | 321.15 Million USD | 28.398% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4189.199% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -312.429% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -490.221% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -101.084% |
| Vaxart, Inc. | 90.72 Million USD | -153.46% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2598.988% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -437.35% |
| Cellectis S.A. | 97.32 Million USD | -136.286% |
| Longeveron Inc. | 21.25 Million USD | -982.136% |
| Repare Therapeutics Inc. | 167.35 Million USD | -37.403% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 83.102% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -203.991% |
| Revolution Medicines, Inc. | 498.76 Million USD | 53.895% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3356.915% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -423.17% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -208.291% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -230.228% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1979.15% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.184% |
| Denali Therapeutics Inc. | 527.23 Million USD | 56.385% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2556.381% |
| Veru Inc. | 101.34 Million USD | -126.895% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -882.416% |
| Cingulate Inc. | 22.75 Million USD | -910.379% |
| Passage Bio, Inc. | 108.38 Million USD | -112.156% |
| Context Therapeutics Inc. | 25.07 Million USD | -817.152% |
| Exicure, Inc. | 14.07 Million USD | -1533.66% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -11.593% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -431.059% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2405.685% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 8.923% |
| Nuvalent, Inc. | 149.49 Million USD | -53.824% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2750.586% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -121.856% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -972.097% |
| OmniAb, Inc. | 83.89 Million USD | -174.097% |
| Anew Medical, Inc. | 1.3 Million USD | -17577.333% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -601.85% |
| Lipocine Inc. | 15.08 Million USD | -1424.88% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -235.636% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -201.967% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -470.403% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -100.233% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -927.314% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 65.376% |
| Ocugen, Inc. | 71.56 Million USD | -221.313% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -144.981% |
| Q32 Bio Inc. | 92.68 Million USD | -148.116% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -986.021% |
| Alumis Inc. Common Stock | 158.17 Million USD | -45.38% |
| Equillium, Inc. | 50.6 Million USD | -354.401% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -268.481% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1553.684% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1118.938% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -389.774% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -112.006% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1755.556% |
| Dominari Holdings Inc. | 23.83 Million USD | -864.774% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2393.332% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1831.251% |
| Bio-Techne Corporation | 563.03 Million USD | 59.158% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 43.75% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 14.438% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -73.843% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1495.684% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -40.476% |
| Nkarta, Inc. | 131.65 Million USD | -74.671% |
| BioCardia, Inc. | 12.12 Million USD | -1797.154% |
| Iterum Therapeutics plc | 47.46 Million USD | -384.44% |